Identification

Name
Decamethonium
Accession Number
DB01245  (APRD00696)
Type
Small Molecule
Groups
Approved
Description

Decamethonium is a short acting depolarizing muscle relaxant or neuromuscular blocking agent, and is used in anesthesia to induce paralysis. It is similar to acetylcholine and acts as a partial agonist of the nicotinic acetylcholine receptor.

Structure
Thumb
Synonyms
  • Decamethonium
  • DECAMETHONIUM ion
  • Decamethonum
  • Decamethylenebis(trimethylammonium)
  • N,N,N,N',n',n'-hexamethyl-1,10-decanediaminium
External IDs
Lopac-D-1260
Product Ingredients
IngredientUNIICASInChI Key
Decamethonium bromide55C6RK944K541-22-0HLXQFVXURMXRPU-UHFFFAOYSA-L
International/Other Brands
Syncurine
Categories
UNII
C1CG1S3T2W
CAS number
156-74-1
Weight
Average: 258.4863
Monoisotopic: 258.303499226
Chemical Formula
C16H38N2
InChI Key
MTCUAOILFDZKCO-UHFFFAOYSA-N
InChI
InChI=1S/C16H38N2/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6/h7-16H2,1-6H3/q+2
IUPAC Name
trimethyl[10-(trimethylazaniumyl)decyl]azanium
SMILES
C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C

Pharmacology

Indication

For use as a skeletal muscle relaxant

Structured Indications
Not Available
Pharmacodynamics

Decamethonium acts as a depolarizing muscle relaxant or neuromuscular blocking agent. It acts as an agonist of nicotinic acetycholine receptors in the motor endplate and causes depolarization. This class of drugs has its effect at the neuromuscular junction by preventing the effects of acetylcholine. Normally, when a nerve stimulus acts to contract a muscle, it releases acetylcholine. The binding of this acetylcholine to receptors causes the muscle to contract. Muscle relaxants play an important role in anesthesia even though they don't provide any pain relief or produce unconsciousness.

Mechanism of action

Binds to the nicotinic acetycholine receptors (by virtue of its similarity to acetylcholine) in the motor endplate and blocks access to the receptors. In the process of binding, the receptor is actually activated - causing a process known as depolarization. Since it is not degraded in the neuromuscular junction, the depolarized membrance remains depolarized and unresponsive to any other impulse, causing muscle paralysis.

TargetActionsOrganism
ANeuronal acetylcholine receptor subunit alpha-2
partial agonist
Human
UAcetylcholinesterase
inhibitor
Human
UNeuronal acetylcholine receptor subunit alpha-4Not AvailableHuman
UNeuronal acetylcholine receptor subunit beta-2Not AvailableHuman
Absorption

Rapidly absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

LD50=190 mg/kg (orally in mice). Prolonged apnoea, neuromuscular paralysis and cardiac arrest may occur.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Decamethonium.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Decamethonium.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Decamethonium.Experimental, Illicit
AcebutololDecamethonium may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Acetylcholine.Approved
AcetyldigitoxinDecamethonium may increase the arrhythmogenic activities of Acetyldigitoxin.Approved
AcetyldigoxinDecamethonium may increase the arrhythmogenic activities of Acetyldigoxin.Experimental
AclarubicinAclarubicin may increase the respiratory depressant activities of Decamethonium.Investigational
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Decamethonium.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Decamethonium.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Decamethonium.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Decamethonium.Experimental, Investigational
AlprenololDecamethonium may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Decamethonium.Approved
AmikacinAmikacin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
AmrubicinAmrubicin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Decamethonium.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Decamethonium.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Decamethonium.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Decamethonium.Approved
annamycinannamycin may increase the respiratory depressant activities of Decamethonium.Investigational
ApramycinApramycin may increase the respiratory depressant activities of Decamethonium.Experimental, Vet Approved
ArbekacinArbekacin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Arecoline.Experimental
ArotinololDecamethonium may increase the bradycardic activities of Arotinolol.Approved, Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Decamethonium.Investigational
AtenololDecamethonium may increase the bradycardic activities of Atenolol.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Decamethonium.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Decamethonium.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Decamethonium.Approved, Vet Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Decamethonium.Approved, Investigational
BefunololDecamethonium may increase the bradycardic activities of Befunolol.Experimental
BekanamycinBekanamycin may increase the respiratory depressant activities of Decamethonium.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Decamethonium.Withdrawn
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Decamethonium.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Decamethonium.Approved, Vet Approved
BetaxololDecamethonium may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Decamethonium is combined with Bethanechol.Approved
BevantololDecamethonium may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Decamethonium.Approved, Investigational
BisoprololDecamethonium may increase the bradycardic activities of Bisoprolol.Approved
BopindololDecamethonium may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Decamethonium.Experimental
Botulinum Toxin Type ABotulinum Toxin Type A may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational
Botulinum Toxin Type BDecamethonium may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BucindololDecamethonium may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Decamethonium.Approved
BufuralolDecamethonium may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideBumetanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
BupranololDecamethonium may increase the bradycardic activities of Bupranolol.Approved
ButylscopolamineThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Decamethonium.Approved, Vet Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Decamethonium.Approved
CarbacholThe risk or severity of adverse effects can be increased when Decamethonium is combined with Carbachol.Approved
CarteololDecamethonium may increase the bradycardic activities of Carteolol.Approved
CarvedilolDecamethonium may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololDecamethonium may increase the bradycardic activities of Celiprolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Cevimeline.Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Decamethonium.Withdrawn
ChlortetracyclineChlortetracycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational, Vet Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Decamethonium.Approved, Investigational
ClindamycinClindamycin may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Decamethonium.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Decamethonium.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Decamethonium.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Decamethonium.Approved
CloranololDecamethonium may increase the bradycardic activities of Cloranolol.Experimental
ColistimethateColistimethate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Decamethonium.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Decamethonium.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Decamethonium.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Decamethonium.Approved
CyclosporineCyclosporine may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational, Vet Approved
CymarinDecamethonium may increase the arrhythmogenic activities of Cymarin.Experimental
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Decamethonium.Approved, Investigational
DaunorubicinDaunorubicin may increase the respiratory depressant activities of Decamethonium.Approved
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Decamethonium.Approved
DemeclocyclineDemeclocycline may increase the neuromuscular blocking activities of Decamethonium.Approved
DeslanosideDecamethonium may increase the arrhythmogenic activities of Deslanoside.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Decamethonium.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Decamethonium.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Decamethonium.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Decamethonium.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Decamethonium.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Decamethonium.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Decamethonium.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Decamethonium.Withdrawn
DibekacinDibekacin may increase the respiratory depressant activities of Decamethonium.Experimental
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Decamethonium.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Decamethonium.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Decamethonium.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Decamethonium.Approved
DigitoxinDecamethonium may increase the arrhythmogenic activities of Digitoxin.Approved, Investigational
DigoxinDecamethonium may increase the arrhythmogenic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Decamethonium may increase the arrhythmogenic activities of Digoxin Immune Fab (Ovine).Approved
DihydrostreptomycinDihydrostreptomycin may increase the respiratory depressant activities of Decamethonium.Investigational, Vet Approved
DipyridamoleThe therapeutic efficacy of Decamethonium can be decreased when used in combination with Dipyridamole.Approved
DoxorubicinDoxorubicin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
DoxycyclineDoxycycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational, Vet Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Decamethonium.Experimental
EpanololDecamethonium may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Epibatidine.Experimental
EpirubicinEpirubicin may increase the respiratory depressant activities of Decamethonium.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Decamethonium.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Decamethonium.Approved
EsmololDecamethonium may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Decamethonium.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Decamethonium.Approved
Etacrynic acidEtacrynic acid may decrease the neuromuscular blocking activities of Decamethonium.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Decamethonium.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Decamethonium.Approved
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Decamethonium.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Decamethonium.Approved
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Decamethonium.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Decamethonium.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Decamethonium.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Decamethonium.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Decamethonium.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Decamethonium.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Decamethonium.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Decamethonium.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Decamethonium.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Decamethonium.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Decamethonium.Approved
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Decamethonium.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Decamethonium.Approved
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Decamethonium.Approved, Investigational, Withdrawn
FramycetinFramycetin may increase the respiratory depressant activities of Decamethonium.Approved
FurosemideFurosemide may decrease the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Decamethonium.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Decamethonium.Approved
GeneticinGeneticin may increase the respiratory depressant activities of Decamethonium.Experimental
GentamicinGentamicin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
GENTAMICIN C1AGENTAMICIN C1A may increase the respiratory depressant activities of Decamethonium.Experimental
GitoformateDecamethonium may increase the arrhythmogenic activities of Gitoformate.Experimental
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Decamethonium.Approved, Investigational, Vet Approved
GPX-150GPX-150 may increase the respiratory depressant activities of Decamethonium.Investigational
GTS-21The risk or severity of adverse effects can be increased when Decamethonium is combined with GTS-21.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Decamethonium.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Decamethonium.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Decamethonium.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Decamethonium.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Decamethonium.Approved, Vet Approved
Hygromycin BHygromycin B may increase the respiratory depressant activities of Decamethonium.Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Decamethonium.Approved
IdarubicinIdarubicin may increase the respiratory depressant activities of Decamethonium.Approved
IndenololDecamethonium may increase the bradycardic activities of Indenolol.Withdrawn
INNO-206INNO-206 may increase the respiratory depressant activities of Decamethonium.Investigational
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Decamethonium.Approved
IsepamicinIsepamicin may increase the respiratory depressant activities of Decamethonium.Experimental
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Decamethonium.Investigational
KanamycinKanamycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational, Vet Approved
LabetalolDecamethonium may increase the bradycardic activities of Labetalol.Approved
Lanatoside CDecamethonium may increase the arrhythmogenic activities of Lanatoside C.Experimental
LandiololDecamethonium may increase the bradycardic activities of Landiolol.Investigational
LevobunololDecamethonium may increase the bradycardic activities of Levobunolol.Approved
LincomycinLincomycin may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
LithiumLithium may increase the neuromuscular blocking activities of Decamethonium.Approved
LobelineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Lobeline.Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Decamethonium.Approved
Magnesium HydroxideMagnesium Hydroxide may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium oxideMagnesium oxide may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium salicylateMagnesium salicylate may increase the neuromuscular blocking activities of Decamethonium.Approved
Magnesium SulfateMagnesium Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Decamethonium.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Decamethonium.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Decamethonium.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Decamethonium.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Decamethonium.Vet Approved
MepindololDecamethonium may increase the bradycardic activities of Mepindolol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Methacholine.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Decamethonium.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decamethonium.Approved, Vet Approved
Methylscopolamine bromideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Decamethonium.Approved
MetildigoxinDecamethonium may increase the arrhythmogenic activities of Metildigoxin.Experimental
MetipranololDecamethonium may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Decamethonium.Approved
MetoprololDecamethonium may increase the bradycardic activities of Metoprolol.Approved, Investigational
MetrizamideMetrizamide may increase the respiratory depressant activities of Decamethonium.Approved
MicronomicinMicronomicin may increase the respiratory depressant activities of Decamethonium.Experimental
MinocyclineMinocycline may increase the neuromuscular blocking activities of Decamethonium.Approved, Investigational
MivacuriumDecamethonium may decrease the neuromuscular blocking activities of Mivacurium.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium.Approved, Vet Approved
NadololDecamethonium may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Decamethonium.Investigational
NeamineNeamine may increase the respiratory depressant activities of Decamethonium.Experimental
NebivololDecamethonium may increase the bradycardic activities of Nebivolol.Approved, Investigational
NeomycinNeomycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
NetilmicinNetilmicin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Nicotine.Approved
OleandrinDecamethonium may increase the arrhythmogenic activities of Oleandrin.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Decamethonium.Investigational
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Decamethonium.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Decamethonium.Experimental, Investigational
OuabainDecamethonium may increase the arrhythmogenic activities of Ouabain.Approved
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Decamethonium.Investigational
OxprenololDecamethonium may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Decamethonium.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Decamethonium.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Decamethonium.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Decamethonium.Approved
ParomomycinParomomycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
PenbutololDecamethonium may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Decamethonium.Approved
PeruvosideDecamethonium may increase the arrhythmogenic activities of Peruvoside.Experimental
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Decamethonium.Experimental
PilocarpineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Pilocarpine.Approved
PindololDecamethonium may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Decamethonium.Approved
PirarubicinPirarubicin may increase the respiratory depressant activities of Decamethonium.Investigational
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Decamethonium.Approved
PiretanidePiretanide may decrease the neuromuscular blocking activities of Decamethonium.Experimental
PirlimycinPirlimycin may increase the neuromuscular blocking activities of Decamethonium.Vet Approved
Platelet Activating FactorDecamethonium may increase the bradycardic activities of Platelet Activating Factor.Experimental
PlazomicinPlazomicin may increase the respiratory depressant activities of Decamethonium.Investigational
PlicamycinPlicamycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational, Withdrawn
Polymyxin B SulfatePolymyxin B Sulfate may increase the neuromuscular blocking activities of Decamethonium.Approved, Vet Approved
PractololDecamethonium may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Decamethonium.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Decamethonium.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Decamethonium.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Decamethonium.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Decamethonium.Experimental, Investigational
ProcainamideProcainamide may increase the neuromuscular blocking activities of Decamethonium.Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Decamethonium.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Decamethonium.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Decamethonium.Approved, Investigational
PropranololDecamethonium may increase the bradycardic activities of Propranolol.Approved, Investigational
ProscillaridinDecamethonium may increase the arrhythmogenic activities of Proscillaridin.Experimental
PuromycinPuromycin may increase the respiratory depressant activities of Decamethonium.Experimental
QuinidineQuinidine may increase the neuromuscular blocking activities of Decamethonium.Approved
QuinineQuinine may increase the neuromuscular blocking activities of Decamethonium.Approved
RapacuroniumDecamethonium may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RibostamycinRibostamycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Decamethonium.Approved
SabarubicinSabarubicin may increase the respiratory depressant activities of Decamethonium.Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Decamethonium.Approved
SisomicinSisomicin may increase the respiratory depressant activities of Decamethonium.Investigational
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Decamethonium.Approved
SotalolDecamethonium may increase the bradycardic activities of Sotalol.Approved
SP1049CSP1049C may increase the respiratory depressant activities of Decamethonium.Investigational
SpectinomycinSpectinomycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational, Vet Approved
StreptomycinStreptomycin may increase the respiratory depressant activities of Decamethonium.Approved, Vet Approved
StreptozocinStreptozocin may increase the respiratory depressant activities of Decamethonium.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Decamethonium.Approved
TalinololDecamethonium may increase the bradycardic activities of Talinolol.Investigational
TertatololDecamethonium may increase the bradycardic activities of Tertatolol.Experimental
TimololDecamethonium may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Decamethonium.Approved
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Decamethonium.Approved
TobramycinTobramycin may increase the respiratory depressant activities of Decamethonium.Approved, Investigational
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Decamethonium.Approved, Investigational
TorasemideTorasemide may decrease the neuromuscular blocking activities of Decamethonium.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Decamethonium.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Decamethonium.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Decamethonium.Approved, Investigational
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Decamethonium.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Decamethonium.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Decamethonium.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Decamethonium.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Decamethonium.Approved
UmeclidiniumThe therapeutic efficacy of Umeclidinium can be decreased when used in combination with Decamethonium.Approved
ValrubicinValrubicin may increase the respiratory depressant activities of Decamethonium.Approved
VancomycinVancomycin may increase the neuromuscular blocking activities of Decamethonium.Approved
VareniclineThe risk or severity of adverse effects can be increased when Decamethonium is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Decamethonium.Approved
Zoptarelin doxorubicinZoptarelin doxorubicin may increase the respiratory depressant activities of Decamethonium.Investigational
ZorubicinZorubicin may increase the respiratory depressant activities of Decamethonium.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB15375
KEGG Compound
C11733
PubChem Compound
2968
PubChem Substance
46507737
ChemSpider
2862
BindingDB
50060582
ChEBI
41934
ChEMBL
CHEMBL1190
Therapeutic Targets Database
DAP000378
PharmGKB
PA164747980
HET
DME
Wikipedia
Decamethonium
PDB Entries
1acl / 1maa / 2xud / 3mes / 5e2i / 5e4j
MSDS
Download (56.6 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)268-270 °CNot Available
water solubilitySubstantialNot Available
Predicted Properties
PropertyValueSource
Water Solubility7.04e-06 mg/mLALOGPS
logP-2.8ALOGPS
logP-4.9ChemAxon
logS-7.7ALOGPS
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity106.95 m3·mol-1ChemAxon
Polarizability35.94 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9862
Blood Brain Barrier+0.9444
Caco-2 permeable+0.7036
P-glycoprotein substrateSubstrate0.5439
P-glycoprotein inhibitor INon-inhibitor0.9679
P-glycoprotein inhibitor IINon-inhibitor0.7809
Renal organic cation transporterNon-inhibitor0.5386
CYP450 2C9 substrateNon-substrate0.8398
CYP450 2D6 substrateNon-substrate0.661
CYP450 3A4 substrateNon-substrate0.5423
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9607
CYP450 2D6 inhibitorNon-inhibitor0.9633
CYP450 2C19 inhibitorNon-inhibitor0.9288
CYP450 3A4 inhibitorNon-inhibitor0.9882
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9899
Ames testNon AMES toxic0.9423
CarcinogenicityCarcinogens 0.6778
BiodegradationNot ready biodegradable0.5263
Rat acute toxicity2.6822 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7991
hERG inhibition (predictor II)Non-inhibitor0.6249
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as decamethonium compounds. These are quaternary ammonium compounds containing a trimethyl-(10-trimethylammoniodecyl)ammonium moiety.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Quaternary ammonium salts
Direct Parent
Decamethonium compounds
Alternative Parents
Tetraalkylammonium salts / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Amines / Organic cations
Substituents
Decamethonium / Tetraalkylammonium salt / Organopnictogen compound / Hydrocarbon derivative / Organic salt / Amine / Organic cation / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
quaternary ammonium ion (CHEBI:41934)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Partial agonist
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Lee C, Jones T: Molecular conformation-activity relationship of decamethonium congeners. Br J Anaesth. 2002 May;88(5):692-9. [PubMed:12067008]
  4. Maneckjee R, Minna JD: Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 1994 Oct;5(10):1033-40. [PubMed:7848904]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Details
2. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Robaire B, Kato G: Effects of edrophonium, eserine, decamethonium, d-tubocurarine, and gallamine on the kinetics of membrane-bound and solubilized eel acetylcholinesterase. Mol Pharmacol. 1975 Nov;11(6):722-34. [PubMed:1207670]
  2. Sinha BK, Chignell CF: Synthesis and biological activity of spin-labeled analogs of biotin, hexamethonium, decamethonium, dichlorisoproterenol, and propranolol. J Med Chem. 1975 Jul;18(7):669-73. [PubMed:239236]
  3. Wu CS, Yang JT: Tacrine protection of acetylcholinesterase from inactivation by diisopropylfluorophosphate: a circular dichroism study. Mol Pharmacol. 1989 Jan;35(1):85-92. [PubMed:2913485]
  4. Seto Y, Shinohara T: Structure-activity relationship of reversible cholinesterase inhibitors including paraquat. Arch Toxicol. 1988 Aug;62(1):37-40. [PubMed:3190453]
  5. Hallek M, Szinicz L: Effects of some mono- and bisquaternary ammonium compounds on the reactivatability of soman-inhibited human acetylcholinesterase in vitro. Biochem Pharmacol. 1988 Mar 1;37(5):819-25. [PubMed:3345199]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [PubMed:14645658]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Eaton JB, Peng JH, Schroeder KM, George AA, Fryer JD, Krishnan C, Buhlman L, Kuo YP, Steinlein O, Lukas RJ: Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells. Mol Pharmacol. 2003 Dec;64(6):1283-94. [PubMed:14645658]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Munoz-Delgado E, Vidal CJ: Kinetic behaviour of acetylcholinesterase from muscle microsomal membranes. Biochem Int. 1986 Oct;13(4):625-32. [PubMed:3801037]
  2. Danilov AF: [Inhibition of cholinesterase in the myoneural synapses by decamethonium and ditilin]. Farmakol Toksikol. 1967 Nov-Dec;30(6):664-9. [PubMed:5598433]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 02:58